<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:b8b6ad7d-ade2-4d51-9923-23e795ce1711,g:84efe52e-868f-4bfc-afad-4651ce8376b8,d:03f8f0e8dec244da985fae12cd530c87--><html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>smmt-20220725</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N180L2ZyYWc6ZjE3YmM0NzJlOGY2NDQ3NWFkN2Y5MDZhZDZlNTcyMmMvdGFibGU6ZTk2NWFiYThiODg5NGU4NzkyMzQwZGUxMzRjM2FiNDQvdGFibGVyYW5nZTplOTY1YWJhOGI4ODk0ZTg3OTIzNDBkZTEzNGMzYWI0NF8wLTEtMS0xLTg5NTM1_d5d10c09-a67b-4da5-a0d2-c626cc976c17">0001599298</ix:nonNumeric><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N180L2ZyYWc6ZjE3YmM0NzJlOGY2NDQ3NWFkN2Y5MDZhZDZlNTcyMmMvdGFibGU6ZTk2NWFiYThiODg5NGU4NzkyMzQwZGUxMzRjM2FiNDQvdGFibGVyYW5nZTplOTY1YWJhOGI4ODk0ZTg3OTIzNDBkZTEzNGMzYWI0NF8xLTEtMS0xLTg5NTM1_7ef6579e-bb5f-4f0a-9539-d93d216c839a">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="smmt-20220725.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001599298</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-07-25</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i03f8f0e8dec244da985fae12cd530c87_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">FORM <ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGV4dHJlZ2lvbjozNDcyYzFhNzk5ODM0N2VhOTdiOTg1NmZlY2NmZGYxNV8zNzg4_90493c9d-2fb4-49a4-8430-c3428958c81e">8-K</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date of Report (Date of Earliest Event Reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGV4dHJlZ2lvbjozNDcyYzFhNzk5ODM0N2VhOTdiOTg1NmZlY2NmZGYxNV8yMjg_b0540248-70c0-4d3f-a790-fda9fd236db3">July 25, 2022</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="padding-left:5.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGFibGU6OGU1Mjc2NGJkMzkyNDY5ZmE4M2ZlNGUzYzI3MTZiMTUvdGFibGVyYW5nZTo4ZTUyNzY0YmQzOTI0NjlmYTgzZmU0ZTNjMjcxNmIxNV8wLTAtMS0xLTg5NTM1_268bb3d0-16d6-40b5-b262-452e5a6bb4de">Summit Therapeutics Inc.</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Its Charter)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGFibGU6OGU1Mjc2NGJkMzkyNDY5ZmE4M2ZlNGUzYzI3MTZiMTUvdGFibGVyYW5nZTo4ZTUyNzY0YmQzOTI0NjlmYTgzZmU0ZTNjMjcxNmIxNV8zLTAtMS0xLTg5NTM1_ea33ad43-c082-4ed7-a65e-32d9c91a4bca">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGFibGU6OGU1Mjc2NGJkMzkyNDY5ZmE4M2ZlNGUzYzI3MTZiMTUvdGFibGVyYW5nZTo4ZTUyNzY0YmQzOTI0NjlmYTgzZmU0ZTNjMjcxNmIxNV8zLTEtMS0xLTg5NTM1_5cf7ded4-17fb-4ecc-8457-f8f3db5b6c9f">001-36866</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGFibGU6OGU1Mjc2NGJkMzkyNDY5ZmE4M2ZlNGUzYzI3MTZiMTUvdGFibGVyYW5nZTo4ZTUyNzY0YmQzOTI0NjlmYTgzZmU0ZTNjMjcxNmIxNV8zLTItMS0xLTg5NTM1_d40cda11-6d89-4a82-8e6f-a5630166c909">37-1979717</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Commission<br/>File Number)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(IRS Employer<br/>Identification No.)</span></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGFibGU6OGU1Mjc2NGJkMzkyNDY5ZmE4M2ZlNGUzYzI3MTZiMTUvdGFibGVyYW5nZTo4ZTUyNzY0YmQzOTI0NjlmYTgzZmU0ZTNjMjcxNmIxNV82LTAtMS0xLTg5NTM1L3RleHRyZWdpb246MWE1Y2FhZGVhZWRhNDk3NmIzZjk3MDllZjAyMzA2MWJfNQ_4098f23a-dc97-45b5-895c-ce9d137aed2f">2882 Sand Hill Road, Suite 106</ix:nonNumeric>, <ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGFibGU6OGU1Mjc2NGJkMzkyNDY5ZmE4M2ZlNGUzYzI3MTZiMTUvdGFibGVyYW5nZTo4ZTUyNzY0YmQzOTI0NjlmYTgzZmU0ZTNjMjcxNmIxNV82LTAtMS0xLTg5NTM1L3RleHRyZWdpb246MWE1Y2FhZGVhZWRhNDk3NmIzZjk3MDllZjAyMzA2MWJfOQ_91bd3260-cc22-486f-8518-52e4790da8d1">Menlo Park</ix:nonNumeric>, <ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGFibGU6OGU1Mjc2NGJkMzkyNDY5ZmE4M2ZlNGUzYzI3MTZiMTUvdGFibGVyYW5nZTo4ZTUyNzY0YmQzOTI0NjlmYTgzZmU0ZTNjMjcxNmIxNV82LTAtMS0xLTg5NTM1L3RleHRyZWdpb246MWE1Y2FhZGVhZWRhNDk3NmIzZjk3MDllZjAyMzA2MWJfMTM_f6e82a53-bfd6-4103-911a-be348a34e0ec">CA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGFibGU6OGU1Mjc2NGJkMzkyNDY5ZmE4M2ZlNGUzYzI3MTZiMTUvdGFibGVyYW5nZTo4ZTUyNzY0YmQzOTI0NjlmYTgzZmU0ZTNjMjcxNmIxNV82LTItMS0xLTg5NTM1_5a0d37cb-3cab-4075-8bc4-bd2e47de6a8d">94025</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Zip Code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Registrant&#8217;s Telephone Number, Including Area Code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGV4dHJlZ2lvbjozNDcyYzFhNzk5ODM0N2VhOTdiOTg1NmZlY2NmZGYxNV8yODk_ac41d7d3-2646-4d5a-a165-38ea31b0203f">617</ix:nonNumeric>-<ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGV4dHJlZ2lvbjozNDcyYzFhNzk5ODM0N2VhOTdiOTg1NmZlY2NmZGYxNV8zNzg5_3eb3d7fb-20c8-468f-99a8-42729dad5657">514-7149</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div style="padding-left:5.65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not applicable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Former Name or Former Address, If Changed Since Last Report)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> General Instruction A.2. below):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGV4dHJlZ2lvbjozNDcyYzFhNzk5ODM0N2VhOTdiOTg1NmZlY2NmZGYxNV8zNzk2_71a819fb-1c27-47a9-8c7b-ab4c2fa05c72">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGV4dHJlZ2lvbjozNDcyYzFhNzk5ODM0N2VhOTdiOTg1NmZlY2NmZGYxNV8zNzkx_2ccdb3a2-0884-48a0-9523-a9b0f53709ed">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGV4dHJlZ2lvbjozNDcyYzFhNzk5ODM0N2VhOTdiOTg1NmZlY2NmZGYxNV8zNzkz_205c47dc-1715-4ae8-876d-d5ceea213462">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGV4dHJlZ2lvbjozNDcyYzFhNzk5ODM0N2VhOTdiOTg1NmZlY2NmZGYxNV8zNzk3_908d9f6b-4156-4f48-b0ed-5d01bf40d3eb">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="padding-left:6.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title of Each Class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGFibGU6YjkwMmMyNjZiYjdhNDlkMmFjZDJiMmMwOGY5ZDIwMDAvdGFibGVyYW5nZTpiOTAyYzI2NmJiN2E0OWQyYWNkMmIyYzA4ZjlkMjAwMF8xLTAtMS0xLTg5NTM1_5b36938a-bded-43fb-b9b2-a7556421991c">Common stock, $0.01&#160;par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGFibGU6YjkwMmMyNjZiYjdhNDlkMmFjZDJiMmMwOGY5ZDIwMDAvdGFibGVyYW5nZTpiOTAyYzI2NmJiN2E0OWQyYWNkMmIyYzA4ZjlkMjAwMF8xLTEtMS0xLTg5NTM1_c74ad011-842c-49df-9522-6b1f86f8467f">SMMT</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGFibGU6YjkwMmMyNjZiYjdhNDlkMmFjZDJiMmMwOGY5ZDIwMDAvdGFibGVyYW5nZTpiOTAyYzI2NmJiN2E0OWQyYWNkMmIyYzA4ZjlkMjAwMF8xLTItMS0xLTg5NTM1_1cf3a1d8-5e91-4c86-9c72-118383cacbb9">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i6ec231d6f56b4f8891192c62058e6db8_D20220725-20220725" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAzZjhmMGU4ZGVjMjQ0ZGE5ODVmYWUxMmNkNTMwYzg3L3NlYzowM2Y4ZjBlOGRlYzI0NGRhOTg1ZmFlMTJjZDUzMGM4N18xL2ZyYWc6MzQ3MmMxYTc5OTgzNDdlYTk3Yjk4NTZmZWNjZmRmMTUvdGV4dHJlZ2lvbjozNDcyYzFhNzk5ODM0N2VhOTdiOTg1NmZlY2NmZGYxNV8zNzk4_0c96d832-c0d5-488f-853f-5457d1cde824">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9744;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:14.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 5.02</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div><span><br/></span></div></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective July 25, 2022, the board of directors (the &#8220;Board&#8221;) of Summit Therapeutics Inc. (the &#8220;Company&#8221;) appointed Dr. Maky Zanganeh to serve as Co-Chief Executive Officer and President of the Company. Dr. Zanganeh will serve as Co-Chief Executive Officer alongside Robert W. Duggan, the Company&#8217;s current Chief Executive Officer. Dr. Zanganeh was formerly the Company&#8217;s Chief Operating Officer. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Zanganeh, age 51, was appointed to the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) on November 11, 2020 and became the Company&#8217;s Chief Operating Officer on November 22, 2020. Dr. Zanganeh founded Maky Zanganeh and Associates in 2015</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Previously, from August 2012 to September 2015, she served as the Chief Operating Officer of Pharmacyclics Inc. She also served as Chief of Staff and Chief Business Officer of Pharmacyclics from December 2011 to July 2012 and Vice President, Business Development from August 2008 to November 2011. Prior to joining Pharmacyclics Inc., Dr. Zanganeh served as President Director General (2007-2008) for the French government bio-cluster project initiative in France, establishing alliances and developing small life science businesses regionally. From September 2003 to August 2008, Dr. Zanganeh served as Vice President of Business Development for Robert W. Duggan &amp; Associates. Dr. Zanganeh also served as worldwide Vice President of Training &amp; Education (2002-2003) and President Director General for Europe, Middle East and Africa (1998-2002) for Computer Motion Inc.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Zanganeh is currently a board member for Pulse Biosciences, Inc. Other than as described below with Mr. Duggan, there are no family relationships between Dr. Zanganeh and any director or executive officer of the Company. Mr. Duggan and Dr. Zanganeh have a personal and familial relationship with each other. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Zanganeh will continue to be compensated pursuant to the terms of the employment agreement entered into between Dr. Zanganeh and the Company on November 22, 2020, in connection with her appointment as Chief Operating Officer. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 26, 2021, the Company entered into a Sublease with Dr. Zanganeh and MZA, for which Dr. Zanganeh serves as Chief Executive Officer and director, consisting of 4,500 square feet of space at 2882 Sand Hill Road, Menlo Park, CA (the &#8220;Sublease&#8221;). The Sublease runs until September 2022. The rent payable under the terms of the Sublease is equivalent to the proportionate share of the rent payable by MZA to the third party landlord, based on the square footage of office space sublet by the Company, and no mark-up has been applied. During the year ended December 31, 2021, payments of $555,750 were made pursuant to the Sublease. Dr. Zanganeh does not have a direct or indirect material interest in any transaction other than the Sublease described above required to be disclosed pursuant to Item 404(a) of Regulation S-K.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There is no arrangement or understanding between Dr. Zanganeh and any other person pursuant to which she was appointed as Co-Chief Executive Officer and President of the Company.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8239; </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.743%"><tr><td style="width:1.0%"></td><td style="width:22.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.138%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Statements and Exhibits.</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d) Exhibits</span></div><div><span><br/></span></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.945%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3pt;padding-right:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Exhibit Number</span></div></td><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.02pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="a2022_prx0726xappointmento.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="a2022_prx0726xappointmento.htm">Press </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="a2022_prx0726xappointmento.htm">Release</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="a2022_prx0726xappointmento.htm">, dated July 26, 2022</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</span></div><div style="padding-left:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SUMMIT THERAPEUTICS&#160;INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: July 26, 2022</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Ankur Dhingra</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "smmt-20220725.htm", "description": "8-K", "secsgml_size_bytes": 42503}]
{"company-data": {"conformed-name": "Summit Therapeutics Inc.", "cik": "0001599298", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-36866", "film-number": "221107464"}, "business-address": {"street1": "2882 SAND HILL ROAD", "street2": "SUITE 106", "city": "MENLO PARK", "state": "CA", "zip": "94025", "phone": "617-514-7149"}, "mail-address": {"street1": "2882 SAND HILL ROAD", "street2": "SUITE 106", "city": "MENLO PARK", "state": "CA", "zip": "94025"}, "former-company": [{"former-conformed-name": "Summit Therapeutics plc", "date-changed": "20150219"}, {"former-conformed-name": "Summit Corp plc", "date-changed": "20140205"}]}
smmt-20220725
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
July 25, 2022
Summit Therapeutics Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
001-36866
37-1979717
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
2882 Sand Hill Road, Suite 106
,
Menlo Park
,
CA
94025
(Address of Principal Executive Offices)
(Zip Code)
Registrant's Telephone Number, Including Area Code:
617
-
514-7149
Not applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common stock, $0.01 par value per share
SMMT
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective July 25, 2022, the board of directors (the "Board") of Summit Therapeutics Inc. (the "Company") appointed Dr. Maky Zanganeh to serve as Co-Chief Executive Officer and President of the Company. Dr. Zanganeh will serve as Co-Chief Executive Officer alongside Robert W. Duggan, the Company's current Chief Executive Officer. Dr. Zanganeh was formerly the Company's Chief Operating Officer.
Dr. Zanganeh, age 51, was appointed to the Company's Board of Directors (the "Board") on November 11, 2020 and became the Company's Chief Operating Officer on November 22, 2020. Dr. Zanganeh founded Maky Zanganeh and Associates in 2015
.
Previously, from August 2012 to September 2015, she served as the Chief Operating Officer of Pharmacyclics Inc. She also served as Chief of Staff and Chief Business Officer of Pharmacyclics from December 2011 to July 2012 and Vice President, Business Development from August 2008 to November 2011. Prior to joining Pharmacyclics Inc., Dr. Zanganeh served as President Director General (2007-2008) for the French government bio-cluster project initiative in France, establishing alliances and developing small life science businesses regionally. From September 2003 to August 2008, Dr. Zanganeh served as Vice President of Business Development for Robert W. Duggan & Associates. Dr. Zanganeh also served as worldwide Vice President of Training & Education (2002-2003) and President Director General for Europe, Middle East and Africa (1998-2002) for Computer Motion Inc.
Dr. Zanganeh is currently a board member for Pulse Biosciences, Inc. Other than as described below with Mr. Duggan, there are no family relationships between Dr. Zanganeh and any director or executive officer of the Company. Mr. Duggan and Dr. Zanganeh have a personal and familial relationship with each other.
Dr. Zanganeh will continue to be compensated pursuant to the terms of the employment agreement entered into between Dr. Zanganeh and the Company on November 22, 2020, in connection with her appointment as Chief Operating Officer.
On March 26, 2021, the Company entered into a Sublease with Dr. Zanganeh and MZA, for which Dr. Zanganeh serves as Chief Executive Officer and director, consisting of 4,500 square feet of space at 2882 Sand Hill Road, Menlo Park, CA (the "Sublease"). The Sublease runs until September 2022. The rent payable under the terms of the Sublease is equivalent to the proportionate share of the rent payable by MZA to the third party landlord, based on the square footage of office space sublet by the Company, and no mark-up has been applied. During the year ended December 31, 2021, payments of $555,750 were made pursuant to the Sublease. Dr. Zanganeh does not have a direct or indirect material interest in any transaction other than the Sublease described above required to be disclosed pursuant to Item 404(a) of Regulation S-K.
There is no arrangement or understanding between Dr. Zanganeh and any other person pursuant to which she was appointed as Co-Chief Executive Officer and President of the Company.
A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number
Description
99.1
Press
Release
, dated July 26, 2022
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
SUMMIT THERAPEUTICS INC.
Date: July 26, 2022
By:
/s/ Ankur Dhingra
Chief Financial Officer